PH12021500006A1 - Methods of treatment and prevention of alzheimer's disease - Google Patents

Methods of treatment and prevention of alzheimer's disease

Info

Publication number
PH12021500006A1
PH12021500006A1 PH12021500006A PH12021500006A PH12021500006A1 PH 12021500006 A1 PH12021500006 A1 PH 12021500006A1 PH 12021500006 A PH12021500006 A PH 12021500006A PH 12021500006 A PH12021500006 A PH 12021500006A PH 12021500006 A1 PH12021500006 A1 PH 12021500006A1
Authority
PH
Philippines
Prior art keywords
methods
disease
alzheimer
subject
prevention
Prior art date
Application number
PH12021500006A
Other languages
English (en)
Inventor
Johan Luthman
Chad J Swanson
Yong Zhang
Shobha Dhadda
Jinping Wang
Lynn Kramer
Original Assignee
Eisai R And D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R And D Man Co Ltd filed Critical Eisai R And D Man Co Ltd
Publication of PH12021500006A1 publication Critical patent/PH12021500006A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH12021500006A 2018-07-24 2021-01-21 Methods of treatment and prevention of alzheimer's disease PH12021500006A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862702659P 2018-07-24 2018-07-24
US201862749614P 2018-10-23 2018-10-23
US201962824162P 2019-03-26 2019-03-26
US201962846902P 2019-05-13 2019-05-13
US201962874684P 2019-07-16 2019-07-16
PCT/US2019/043067 WO2020023530A2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease

Publications (1)

Publication Number Publication Date
PH12021500006A1 true PH12021500006A1 (en) 2021-09-13

Family

ID=67551415

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021500006A PH12021500006A1 (en) 2018-07-24 2021-01-21 Methods of treatment and prevention of alzheimer's disease

Country Status (13)

Country Link
US (1) US20210324056A1 (enExample)
EP (1) EP3826674A2 (enExample)
JP (2) JP7541505B2 (enExample)
KR (1) KR20210039402A (enExample)
CN (2) CN112805031A (enExample)
AU (1) AU2019309938A1 (enExample)
BR (1) BR112021001272A2 (enExample)
CA (1) CA3107370A1 (enExample)
IL (3) IL280315B2 (enExample)
MX (1) MX2021000778A (enExample)
PH (1) PH12021500006A1 (enExample)
TW (1) TW202019471A (enExample)
WO (1) WO2020023530A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
PH12022552172A1 (en) * 2020-03-20 2023-12-11 Eisai R&D Man Co Ltd High concentration anti-a㟠protofibril antibody formulations and methods of use thereof
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
JP2023535024A (ja) 2020-07-23 2023-08-15 オター プロシーナ リミテッド 抗ａベータ抗体
US20230302009A1 (en) * 2020-08-12 2023-09-28 The Cleveland Clinic Foundation Bace1 inhibitor treatment for suppressing cytokine storm
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
US20250051427A1 (en) * 2021-12-17 2025-02-13 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
WO2023111618A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
KR20240142535A (ko) * 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
BRPI0709050B1 (pt) * 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US20100317850A1 (en) 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
PT2448968T (pt) 2009-06-29 2021-04-30 Bioarctic Ab ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL
EP2538982A4 (en) * 2010-02-25 2016-02-17 Janssen Alzheimer Immunotherap PET MONITORING OF IMMUNOTHERAPY TARGETED ON A-BETA
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
SG191710A1 (en) 2011-01-21 2013-08-30 Eisai R&D Man Co Ltd Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
SI3166970T1 (sl) 2014-07-10 2021-09-30 Bioarctic Ab Izboljšana A-beta protofibril vezavna protitelesa
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN114019170A (zh) * 2016-01-20 2022-02-08 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
WO2017194789A1 (en) * 2016-05-13 2017-11-16 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
IL316169A (en) 2016-10-27 2024-12-01 Eisai R&D Man Co Ltd Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
AU2019309938A1 (en) 2021-03-11
IL310132A (en) 2024-03-01
KR20210039402A (ko) 2021-04-09
JP2024112859A (ja) 2024-08-21
IL280315B2 (en) 2024-06-01
IL310132B1 (en) 2025-11-01
CA3107370A1 (en) 2020-01-30
EP3826674A2 (en) 2021-06-02
US20210324056A1 (en) 2021-10-21
WO2020023530A2 (en) 2020-01-30
CN118924896A (zh) 2024-11-12
IL280315B1 (en) 2024-02-01
TW202019471A (zh) 2020-06-01
JP2021532126A (ja) 2021-11-25
WO2020023530A3 (en) 2020-03-12
JP7541505B2 (ja) 2024-08-28
CN112805031A (zh) 2021-05-14
MX2021000778A (es) 2021-03-31
BR112021001272A2 (pt) 2021-04-27
IL280315A (en) 2021-03-25
IL323583A (en) 2025-11-01

Similar Documents

Publication Publication Date Title
PH12021500006A1 (en) Methods of treatment and prevention of alzheimer's disease
PH12020500555A1 (en) Esketamine for the treatment of depression
MX2021002322A (es) Nuevos metodos.
CA3114021C (en) METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
AU2017291414B2 (en) Anti-N3pGLu amyloid beta peptide antibodies and uses thereof
MX2023005628A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2024010655A (es) Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
WO2019175260A3 (en) Modified oligonucleotides for use in treatment of tauopathies
MX2024002567A (es) Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas.
MX2022001287A (es) Composiciones y metodos de uso de celulas madre multipotentes para reducir la enfermedad y mejorar el bienestar.
WO2021023069A8 (zh) Tpk作为靶点在阿尔茨海默病的应用
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
MX2020007941A (es) Metodo para prevenir o tratar enfermedad de alzheimer.
MX2021009488A (es) Uso de vibegron para tratar la vejiga hiperactiva.
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EP4523750A3 (en) Methods of reducing cerebrovascular events in patients with fabry disease
EA201170970A1 (ru) Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом
MX2021006209A (es) Montelukast para el tratamiento de la osteoartritis erosiva de la mano.
WO2023049534A3 (en) Subcutaneously administered foslevodopa/foscarbidopa treatments for advanced parkinson's disease
WO2022192639A3 (en) Anti-n3pglu amyloid beta antibodies and uses thereof
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor